 21. Any patient who is on standard anticoagulant therapy INR targeted at 2.0 to 3.0 or treatment for deep vein thrombosis, or grade 3 or 4 venous thrombosis Table 1, is not eligible to enroll in the study. Patients who are on stable, low-dose heparin or warfarin therapy may be eligible for the study. 